Suzanne Cory-Projects

Suzanne Cory-Projects


BH3 mimetic treatment of acute myeloid leukaemia

Using models of acute myeloid leukaemia (AML) induced by fusion oncoproteins that provoke human AML, we are analysing:

  1. Which BH3-only proteins are critical for the action of conventional AML therapeutics.
  2. Whether BH3 mimetics can be used in combination with these drugs to improve therapeutic outcomes.
Impact of over-expression of Mcl-1 on haematopoiesis and acute myeloid leukaemia

We are investigating the impact of elevated Mcl-1 on the lymphoproliferative disease caused by mutation of the apoptosis-inducing receptor Fas. We are also determining the impact of elevated Mcl-1 on the onset and severity of AML provoked by retroviral expression of the fusion oncoprotein MLL/AF9; and the responsiveness of MLL/AF9 AMLs to cancer therapeutics, including BH3 mimetics.

A1 and leukaemogenesis

We are investigating which models of leukaemogenesis depend on A1, a poorly studied anti-apoptotic member of the Bcl-2 family, with the goal of developing better modalities of treatment.

Tumorigenic impact of loss of the Myc antagonist Mnt

Mnt antagonizes Myc by binding to Myc’s obligate binding partner Max. We have found that Myc-driven lymphomagenesis is slowed in a mnt+/- background, a phenotype consistent with increased susceptibility to apoptosis. We will now use CRISPR/Cas9 technology to further reduce Mnt levels and determine the impact on cell cycle and apoptosis.